While the use of inhaled medicines for the treatment of certain lung diseases has been well-established, the use of these medicines for other diseases has not advanced as quickly. Treatments for serious diseases, such as cancer and diseases of the central nervous system, are often developed as oral medicines. While these treatments can be effective, their dose is often limited by adverse events. These adverse events are often related to gastrointestinal findings, such as nausea, vomiting, or abdominal pain, or related to liver findings, such as elevated liver enzymes or other signs of liver damage. In addition, many oral treatments suffer from poor oral bioavailability, which results in higher doses needed to be given to achieve the desired therapeutic effect. In these situations, inhaled therapies can offer a significant advantage.
Since much of an inhaled medicine dose travels to the lung and not the stomach, inhaled therapies can avoid many of the associated gastrointestinal or liver effects. In addition, because many drugs can be efficiently absorbed through the lung if the right technology is harnessed, the dose required can be much lower, which therefore lowers the bodys overall exposure to the medicine.
We at Transpire Bio have identified a number of serious diseases with substantial unmet medical need where inhaled medicines could offer a significant therapeutic advancement.